Center of Nanotechnology for Treatment, Understanding, *

癌症治疗、理解和监测纳米技术卓越中心 (纳米肿瘤)已经建立，以完善实用的纳米技术基础，以诊断，治疗和 监测癌症。我们的目标是开发一个多功能的“智能母舰”平台，它将：(1) 避开网状内皮系统和免疫系统，同时特异性地附着在肿瘤和其 血管系统；(2)在肿瘤部位组装多功能复合体；(3)提供两者的有效载荷 原位激活的纳米传感器和治疗药物。纳米肿瘤中心聚集了一位 来自加州大学圣地亚哥分校、圣巴巴拉分校、欧文分校和河滨分校的调查小组 校园、伯纳姆研究所和NanoBioNexus。纳米肿瘤中心的研究计划是 由六个互动项目组成，每个项目都利用新开发的独特技术，当 结合在一起将导致我们的目标的实现。这六个项目的重点是(1)生产 肿瘤靶向、无毒纳米粒，(2)载药纳米多孔微平台的研制 纳米传感器、成像和治疗剂，(3)创建肿瘤定向扩增系统 传感和药物输送，(4)肿瘤分子纯化装置的构建和 纳米尺度的表征，(5)新的纵向计算方法的应用 监测和分析肿瘤进展和治疗反应，以及(6)原位组装和 利用智能纳米技术平台提供靶向治疗。该中心已成立 使用新的工程型决策和工作流模型：已经提出了多种方法来 处理每个项目，并根据里程碑的完成情况做出进行或不进行的决定。纳诺图莫尔 项目负责人此前创建了20多家成功的生物技术公司，拥有 总市值超过20亿美元，证明他们有能力将发现转化为有用的 市场上的应用程序。纳米肿瘤中心开发临床应用的意图 来自加州大学圣迭戈分校癌症中心的临床医生的战略作用也证明了平台，以及 来自大公司(通用电气、霍尼韦尔、Nanogen、企业)的参与者将在 对研究进行评估。

The Center of Excellence of NANOtechnology for Treatment, Understanding, and Monitoring of Cancer (NANO-TUMOR) has been established to perfect a practical nanotechnology base to diagnose, treat, and monitor cancers. Our goal is the development, of a multi-functional "smart mothership" platform that will: (1) evade the reticuloendothelial system and immune system, while attaching specifically to the tumor and its vasculature; (2) assemble a multi-functional complex at the tumor site; (3) deliver payloads of both nanosensors and therapeutics that are activated in situ. The NANO-TUMOR Center has brought together a team of investigators from the University of California, San Diego, Santa Barbara, Irvine, and Riverside campuses, the Burnham Institute and NanoBioNexus. The NANO-TUMOR Center research program is comprised of six interacting projects, each utilizing newly developed and unique technologies that when integrated together willlead to the realization of our goal. The six projects focus on (1) the production of tumor-targeted, non-toxic nanoparticles, (2) the development of a nanoporous micro-platform carrying nanosensors, imaging and therapeutic agents, (3) the creation of tumor-directed amplification systems for sensing and drug delivery, (4) the construction of devices for tumor molecule purification and characterization at a nanoscale level, (5) the application of new computational methods for longitudinal monitoring and analyses of tumor progression and response to therapy, and (6) the in situ assembly and delivery of targeted therapeutics with a smart nanotechnology platform. The Center has been organized using a novel, engineering-type decision and workflow model: Multiple approaches have been proposed to address each project, with go/no go decisions made based on achievement of milestones. The NANOTUMOR project leaders have previously founded more than 20 successful biotechnology companies, with a total market value of over two billion dollars, evidence of their ability to move discoveries to useful applications in the marketplace. The intent of the NANO-TUMOR Center to develop clinically useful platforms is also demonstrated by the strategic role that clinicians from the UCSD Cancer Center, and participants from major corporations (General Electric, Honeywell, Nanogen, Enterprise) will play in evaluating the research.